Zura Bio
ZURA
95 hedge funds and large institutions have $429M invested in Zura Bio in 2026 Q2 according to their latest regulatory filings, with 26 funds opening new positions, 33 increasing their positions, 18 reducing their positions, and 24 closing their positions.
83% more repeat investments, than reductions
Existing positions increased: 33 | Existing positions reduced: 18
33% more call options, than puts
Call options by funds: $838K | Put options by funds: $631K
9% more capital invested
Capital invested by funds: $392M → $429M (+$37.1M)
7.15% more ownership
Funds ownership: 69.62% → 76.78% (+7.2%)
1% more funds holding
Funds holding: 94 → 95 (+1)
8% more first-time investments, than exits
New positions opened: 26 | Existing positions closed: 24
50% less funds holding in top 10
Funds holding in top 10: 2 → 1 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
MB
MPM BioImpact
Boston,
Massachusetts
|
+$21.3M |
| 2 |
BlackRock
New York
|
+$15M |
| 3 |
SVCM
Saturn V Capital Management
Austin,
Texas
|
+$6.48M |
| 4 |
ACM
ADAR1 Capital Management
Austin,
Texas
|
+$5.38M |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
+$5.03M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
P
Pfizer
New York
|
-$11M |
| 2 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
-$8.63M |
| 3 |
Millennium Management
New York
|
-$6.53M |
| 4 |
AAA
Affinity Asset Advisors
New York
|
-$5.24M |
| 5 |
Point72 Asset Management
Stamford,
Connecticut
|
-$5.19M |
ZURA Hedge Fund Activity: Q2 2026 in Review
95 of the 8,318 institutional investors tracked by Wall St. Rank reported a position in Zura Bio (ZURA) for Q2 2026, worth a combined $429M — up 9.5% from $392M a quarter earlier.
Buyers outnumbered sellers: 26 funds opened new ZURA positions and 24 closed out — a net gain of 2 holders — while 33 added to existing stakes and 18 trimmed.
The largest buyer was MPM BioImpact, opening a new position worth an estimated $21.3M. The largest seller was Pfizer, cutting an estimated $11M.
- 95 institutional investors held Zura Bio (ZURA) as of Q2 2026, up from 94 in Q1 2026.
- Funds reported $429M of Zura Bio stock for Q2 2026, up 9.5% quarter-over-quarter.
- 26 funds opened new Zura Bio positions in Q2 2026 and 24 closed out, a net change of +2 holders.
- The largest Zura Bio buyer in Q2 2026 was MPM BioImpact, an estimated $21.3M added.
- The largest Zura Bio seller in Q2 2026 was Pfizer, an estimated $11M sold.
Based on aggregated 13F filings for Q2 2026.